The oral BTK* inhibitor evobrutinib at a dose of 75 mg/day reduced the number of gadolinium-enhancing lesions in patients with relapsing multiple sclerosis (MS), according to a phase II trial presented at AAN 2019.
A new orally dissolving tablet (ODT) formulation of rimegepant showed rapid onset of action and sustained benefits in terms of pain relief and symptom improvement in patients with acute migraine, the 303 study finds.
A novel three-drug cocktail, PXT3003, reduces disability in patients with Charcot-Marie-Tooth Type 1A disease (CMT1A) along with a favourable safety profile, according to the PLEO-CMT study presented at AAN 2019, providing hope for a rare disease which so far has no cure.
The terminal complement inhibitor eculizumab significantly lowered relapse risk in patients with neuromyelitis optical spectrum disorder (NMOSD) who were positive for aquaporin-4 antibodies (AQP4-IgG) compared with placebo, according to the PREVENT* study presented at AAN 2019.
A 10 or 20 mg/kg daily dose of cannabidiol could almost halve the risk of seizures in children with Dravet syndrome, according to the phase III GWPCARE2* study presented at the American Academy of Neurology annual meeting (AAN 2019).
Use of the antihypertensive drug isradipine did not reduce the progression of Parkinson’s disease, according to the STEADY-PD III* study presented at the American Academy of Neurology annual meeting (AAN 2019).
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.